224 related articles for article (PubMed ID: 22068222)
1. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.
Cho JH; Kim KM; Kwon M; Kim JH; Lee J
Invest New Drugs; 2012 Oct; 30(5):2008-14. PubMed ID: 22068222
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Lee SJ; Kim TM; Kim YJ; Jang KT; Lee HJ; Lee SN; Ahn MS; Hwang IG; Lee S; Lee MH; Lee J
Oncologist; 2015 Nov; 20(11):1312-9. PubMed ID: 26424760
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J; Carvajal RD; Dummer R; Hauschild A; Daud A; Bastian BC; Markovic SN; Queirolo P; Arance A; Berking C; Camargo V; Herchenhorn D; Petrella TM; Schadendorf D; Sharfman W; Testori A; Novick S; Hertle S; Nourry C; Chen Q; Hodi FS
Ann Oncol; 2017 Jun; 28(6):1380-1387. PubMed ID: 28327988
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Carvajal RD; Lawrence DP; Weber JS; Gajewski TF; Gonzalez R; Lutzky J; O'Day SJ; Hamid O; Wolchok JD; Chapman PB; Sullivan RJ; Teitcher JB; Ramaiya N; Giobbie-Hurder A; Antonescu CR; Heinrich MC; Bastian BC; Corless CL; Fletcher JA; Hodi FS
Clin Cancer Res; 2015 May; 21(10):2289-96. PubMed ID: 25695690
[TBL] [Abstract][Full Text] [Related]
5. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J; Chevret S; Jouary T; Dalac S; Dalle S; Guillot B; Arnault JP; Avril MF; Bedane C; Bens G; Pham-Ledard A; Mansard S; Grange F; Machet L; Meyer N; Legoupil D; Saiag P; Idir Z; Renault V; Deleuze JF; Hindie E; Battistella M; Dumaz N; Mourah S; Lebbe C;
J Invest Dermatol; 2018 Jan; 138(1):58-67. PubMed ID: 28843487
[TBL] [Abstract][Full Text] [Related]
6. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
7. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
8. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J; Marais R; Porta N; Gonzalez de Castro D; Parsons L; Messiou C; Stamp G; Thompson L; Edmonds K; Sarker S; Banerji J; Lorigan P; Evans TRJ; Corrie P; Marshall E; Middleton MR; Nathan P; Nicholson S; Ottensmeier C; Plummer R; Bliss J; Valpione S; Turajlic S
Cell Rep Med; 2024 Mar; 5(3):101435. PubMed ID: 38417447
[TBL] [Abstract][Full Text] [Related]
10. A potential role for nilotinib in KIT-mutated melanoma.
Tran A; Tawbi HA
Expert Opin Investig Drugs; 2012 Jun; 21(6):861-9. PubMed ID: 22500535
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of dasatinib in advanced melanoma.
Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
[TBL] [Abstract][Full Text] [Related]
12. C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.
Alkeraye S; Dadban A; Lok C; Arnault JP; Chaby G
Dermatol Online J; 2016 Jan; 22(1):. PubMed ID: 26990482
[TBL] [Abstract][Full Text] [Related]
13. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
[TBL] [Abstract][Full Text] [Related]
15. Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.
Wei X; Mao L; Chi Z; Sheng X; Cui C; Kong Y; Dai J; Wang X; Li S; Tang B; Lian B; Yan X; Bai X; Zhou L; Guo J; Si L
Oncol Res; 2019 Mar; 27(4):495-501. PubMed ID: 30075827
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib therapy for melanoma patients with KIT mutations.
Minor DR; Kashani-Sabet M; Garrido M; O'Day SJ; Hamid O; Bastian BC
Clin Cancer Res; 2012 Mar; 18(5):1457-63. PubMed ID: 22261812
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
Murer C; Kränzlin-Stieger P; French LE; Dummer R; Goldinger SM
Melanoma Res; 2017 Aug; 27(4):396-398. PubMed ID: 28410286
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A
Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Cauchi C; Somaiah N; Engstrom PF; Litwin S; Lopez M; Lee J; Davey M; Bove B; von Mehren M
Cancer Chemother Pharmacol; 2012 Apr; 69(4):977-82. PubMed ID: 22119758
[TBL] [Abstract][Full Text] [Related]
20. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours.
Pantaleo MA; Nannini M; Saponara M; Gnocchi C; Di Scioscio V; Lolli C; Catena F; Astolfi A; Di Battista M; Biasco G;
Anticancer Drugs; 2012 Jun; 23(5):567-72. PubMed ID: 22430048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
